This company has been marked as potentially delisted and may not be actively trading.

Day One Biopharmaceuticals (DAWN) Stock Forecast & Price Target

Get the Latest News and Ratings for DAWN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DAWN Analyst Ratings Over Time

Type	Current Forecast 5/7/25 to 5/7/26	1 Month Ago 4/7/25 to 4/7/26	3 Months Ago 2/6/25 to 2/6/26	1 Year Ago 5/7/24 to 5/7/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$23.29	$23.29	$25.71	$30.57
Forecasted Upside	8.15% Upside	8.51% Upside	125.37% Upside	385.26% Upside
Consensus Rating	Hold	Hold	Moderate Buy	Buy

DAWN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DAWN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Day One Biopharmaceuticals Stock vs. The Competition

Type	Day One Biopharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	8.15% Upside	913.16% Upside	14.02% Upside
News Sentiment Rating	Positive News See Recent DAWN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
3/11/2026	JPMorgan Chase & Co. 3 of 5 stars	Anupam Rama 5 of 5 stars	Reiterated Rating	Overweight ➝ Neutral	$27.00 ➝ $21.50	+0.91%
3/10/2026	HC Wainwright 3 of 5 stars	Andres Y. Not Rated	Reiterated Rating	Buy ➝ Neutral	$22.00 ➝ $21.50	+0.80%
3/9/2026	Wedbush 5 of 5 stars	Robert Driscoll 5 of 5 stars	Reiterated Rating	Outperform ➝ Neutral	$30.00 ➝ $21.50	+1.42%
3/6/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tara Bancroft Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/6/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
3/6/2026	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Soumit Roy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $21.50	+1.42%
3/6/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ami Fadia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/25/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
12/29/2025	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
11/5/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kelsey Goodwin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$25.00 ➝ $26.00	+215.73%
Get the Latest News and Ratings for DAWN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/25/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrea Tan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$39.00 ➝ $27.00	+235.40%
1/7/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$28.00 ➝ $25.00	+100.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:34 AM ET.

DAWN Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Day One Biopharmaceuticals is $23.29, with a high forecast of $34.00 and a low forecast of $17.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DAWN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DAWN, but not buy additional shares or sell existing shares.
: According to analysts, Day One Biopharmaceuticals's stock has a predicted upside of 8.15% based on their 12-month stock forecasts.
: Over the previous 90 days, Day One Biopharmaceuticals's stock had 5 downgrades by analysts.
: Day One Biopharmaceuticals has been rated by research analysts at HC Wainwright, JonesTrading, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer, TD Cowen, Wedbush, and Zacks Research in the past 90 days.
: Analysts like Day One Biopharmaceuticals less than other "medical" companies. The consensus rating score for Day One Biopharmaceuticals is 2.00 while the average consensus rating score for "medical" companies is 2.30. Learn more on how DAWN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Day One Biopharmaceuticals Recommendations

This page (NASDAQ:DAWN) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.